Osaka, Japan

Konomi Matsuo

This inventor holds 1 USPTO granted patent. Top assignee: Kanebo, Limited. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Konomi Matsuo. Retrieved from https://idiyas.com/inventor/konomi-matsuo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Konomi Matsuo: Innovator in Pharmaceutical Chemistry

Konomi Matsuo is a prominent inventor based in Osaka, Japan. She has made significant contributions to the field of pharmaceutical chemistry, particularly through her innovative research and development efforts.

Latest Patents

Konomi Matsuo holds a patent for an acylphenylglycine derivative, which serves as a preventive and remedy for various diseases. This patent showcases her dedication to advancing medical science and improving health outcomes.

Career Highlights

Matsuo is currently employed at Kanebo, Limited, where she applies her expertise in pharmaceutical research. Her work at Kanebo has allowed her to explore new avenues in drug development and contribute to the company's mission of enhancing health and beauty.

Collaborations

Throughout her career, Konomi has collaborated with notable colleagues, including Ryoichi Hirayama and Takahiro Tsukida. These partnerships have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Konomi Matsuo is a trailblazer in her field, with a focus on developing effective treatments for diseases. Her contributions to pharmaceutical chemistry and her collaborative spirit highlight her importance in the industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…